Epclusa is first treatment for all forms of the disease
Drug will mainly be used in patients with genotypes 2 and 3
Gilead Sciences Inc.’s hepatitis C drug was approved by U.S. regulators for all forms of the viral disease, making it the first treatment with such a comprehensive label.
The drug, called Epclusa, can be used by patients with any of the six genotypes of hepatitis C, the U.S. Food and Drug Administration said Tuesday in a statement. The liver disease affects 130 million to 150 million people globally, according to the World Health Organization.
Gilead has set a list price of $74,760 for a 12-week course of treatment, Chief Executive Officer John Milligan said by telephone. That’s lower than the list prices of its best-selling treatments Sovaldi, at $84,000, and Harvoni, $94,500. The Foster City, California-based company has been criticized in the past for the costs of its drugs.